SRI-011381
CAS No. 1629138-41-5
SRI-011381( SRI-011381 | SRI 011381 | SRI011381 )
Catalog No. M17348 CAS No. 1629138-41-5
SRI-011381, a new-type agonist of the TGF-beta signaling pathway, is utilized in the treatment of Alzheimer's disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 36 | In Stock |
|
| 5MG | 58 | In Stock |
|
| 10MG | 102 | In Stock |
|
| 25MG | 215 | In Stock |
|
| 50MG | 357 | In Stock |
|
| 100MG | 590 | In Stock |
|
| 200MG | 826 | In Stock |
|
| 500MG | 1224 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSRI-011381
-
NoteResearch use only, not for human use.
-
Brief DescriptionSRI-011381, a new-type agonist of the TGF-beta signaling pathway, is utilized in the treatment of Alzheimer's disease.
-
DescriptionSRI-011381 is an agonist of the TGF-beta signaling pathway for treatment of Alzheimer's disease.
-
In Vitro——
-
In VivoAnimal Model:YAPGFAP-CKO mice bearing experimental autoimmune encephalomyelitis (EAE)Dosage:30 mg/kg .Administration:Intraperitoneally injection; every 2 d; for 22 days Result:Significantly inhibited inflammatory infiltration and relieved the loss of neurons in YAPGFAP-CKO EAE mice.
-
SynonymsSRI-011381 | SRI 011381 | SRI011381
-
PathwayCell Cycle/DNA Damage
-
TargetPARP
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1629138-41-5
-
Formula Weight329.48
-
Molecular FormulaC20H31N3O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (151.75 mM)
-
SMILESO=C(NC1=NC2=CC=C(CN3CCC(C(C)(O)C)CC3)C=C2N1[C@H]4CC[C@@H](C(NC(C)C)=O)CC4)C5=CC=C(F)C=C5
-
Chemical NameN'-Cyclohexyl-N-(phenylmethyl)-N-(4-piperidinylmethyl)-urea
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
ARTD10/PARP10-IN-1
ARTD10/PARP10-IN-1 is a potent PARP inhibitor of the mono-ADP ribosyltransferases ARTD7/PARP15, ARTD8/PARP14, ARTD10/PARP10 and poly ADP-ribose polymerase-1 (ARTD1/PARP1), with potential anticancer and antitumour activity for the study of prostate and breast cancers.
-
Senaparib
Senaparib is a novel highly potent and selective oral PARP1/2 inhibitor with strong antitumor activity.
-
RBN-2397
RBN-2397 (0.0001-100 μM; 24 hours) inhibits cells proliferation with an IC50 value of 20 nM in NCI-H1373 lung cancer cells.
Cart
sales@molnova.com